カテゴリ： GlobalData, イギリス, 企業調査

Tiziana Life Sciences Plc (TILS)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Tiziana Life Sciences Plc (TILS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10129
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：65
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Tiziana Life Sciences Plc (Tiziana), formerly Alexander David Investments Plc, is a clinical stage biotechnology company that discovers and develops drugs to treat diseases in oncology and immunology. The company’s lead product candidate, TZLS-201, intended for the treatment of thymic carcinoma. Its other clinical programmes include TZLS-401, a human engineered anti-human CD3 antibody intended for the treatment of autoimmune and inflammatory diseases. The company’s preclinical stage candidates include TZLS-501, a fully human anti-IL-6R monoclonal antibody targeting the interleukin-6 receptor; and StemPrintER, a multi-gene signature assay intended for the treatment of patients with breast cancer. Tiziana is headquartered in London, the UK.

Tiziana Life Sciences Plc (TILS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Tiziana Life Sciences Plc, Medical Devices Deals, 2012 to YTD 2018 10
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Tiziana Life Sciences Acquires Bio-Repository from Shardna for USD0.3 Million 12
Licensing Agreements 13
Tiziana Life Sciences Enters into Licensing Agreement with Brigham and Women’s Hospital 13
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune 14
Tiziana Life Sciences Enters into Agreement with Cardiff University 15
Tiziana Life Sciences Enters into Licensing Agreement with Nerviano Medical Sciences for Milciclib 16
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune for Foralumab 18
Tiziana Life Sciences Enters into Licensing Agreement with Cardiff University 19
Equity Offering 20
Tiziana Life Sciences to Raise USD10 Million in Public Offering of ADS 20
Tiziana Life Sciences Raises USD0.8 Million in Private Placement of Shares 21
Tiziana Life Sciences Raises USD0.1 Million in Private Placement of Shares 22
Tiziana Life Sciences Raises USD0.2 Million in Private Placement of Shares and Warrants 23
Tiziana Life Sciences Raises USD0.3 Million in Private Placement of Shares 24
Tiziana Life Sciences Raises USD0.4 Million in Private Placement of Shares 25
Tiziana Life Sciences Raises USD0.2 Million in Private Placement of Shares 26
Tiziana Life Sciences Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 27
Tiziana Life Sciences Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 28
Tiziana Life Sciences Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 29
Tiziana Life Sciences Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 30
Tiziana Life Sciences Raises USD3.8 Million in Private Placement of Shares 31
Tiziana Life Sciences Completes Placement for USD3.3 Million 32
Acquisition 33
Alexander David Investments Completes Acquisition of Tiziana Pharma in Reverse Takeover Transaction 33
Tiziana Life Sciences Plc – Key Competitors 34
Tiziana Life Sciences Plc – Key Employees 35
Tiziana Life Sciences Plc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Sep 24, 2018: Tiziana Life Sciences: Interim Results for the Six Months Ended 30 June 2018 37
Jun 07, 2018: Tiziana Life Sciences: Financial Results for the Year Ended 31 December 2017 39
Sep 29, 2017: Tiziana Life Sciences: Interim Results for the Six Months Ended 30 June 2017 46
May 23, 2017: Tiziana Life Sciences: Financial Results for the Year Ended 31 December 2016 52
Corporate Communications 53
Jun 12, 2017: Tiziana Life Sciences Strengthens Unique Research Focus by Appointing Dr Kunwar Shailubhai as Chief Executive Officer 53
Mar 14, 2017: Tiziana Life Sciences Appoints Dr. Arun Sanyal to its Scientific Advisory Board 55
Product News 56
07/28/2017: Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases 56
03/14/2017: Tiziana Life Sciences Appoints Dr. Arun Sanyal to its Scientific Advisory Board 57
Clinical Trials 58
Dec 08, 2017: Tiziana Life Sciences Announces Safety of Milciclib in a Phase 2a Trial in Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Patients 58
Nov 23, 2017: Tiziana Life Sciences Announces that Milciclib Met its Primary Endpoint in Two Phase II Clinical Trials in Patients with Thymic Carcinoma and Thymoma” 59
Sep 06, 2017: Development of a Proprietary Oral Formulation of Foralumab, a Fully Human Anti-CD3 mAb, for use in an Upcoming Phase 2a Clinical Trial in NASH 61
Jul 19, 2017: Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma 62
Apr 24, 2017: Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma 63
Apr 21, 2017: Tiziana Life Sciences Announces Publication of Peer-Reviewed Paper from Positive Clinical Trial of Milciclib in Patients with Refractory Solid Tumours 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tiziana Life Sciences Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Tiziana Life Sciences Plc, Medical Devices Deals, 2012 to YTD 2018 10
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Tiziana Life Sciences Acquires Bio-Repository from Shardna for USD0.3 Million 12
Tiziana Life Sciences Enters into Licensing Agreement with Brigham and Women's Hospital 13
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune 14
Tiziana Life Sciences Enters into Agreement with Cardiff University 15
Tiziana Life Sciences Enters into Licensing Agreement with Nerviano Medical Sciences for Milciclib 16
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune for Foralumab 18
Tiziana Life Sciences Enters into Licensing Agreement with Cardiff University 19
Tiziana Life Sciences to Raise USD10 Million in Public Offering of ADS 20
Tiziana Life Sciences Raises USD0.8 Million in Private Placement of Shares 21
Tiziana Life Sciences Raises USD0.1 Million in Private Placement of Shares 22
Tiziana Life Sciences Raises USD0.2 Million in Private Placement of Shares and Warrants 23
Tiziana Life Sciences Raises USD0.3 Million in Private Placement of Shares 24
Tiziana Life Sciences Raises USD0.4 Million in Private Placement of Shares 25
Tiziana Life Sciences Raises USD0.2 Million in Private Placement of Shares 26
Tiziana Life Sciences Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 27
Tiziana Life Sciences Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 28
Tiziana Life Sciences Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 29
Tiziana Life Sciences Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 30
Tiziana Life Sciences Raises USD3.8 Million in Private Placement of Shares 31
Tiziana Life Sciences Completes Placement for USD3.3 Million 32
Alexander David Investments Completes Acquisition of Tiziana Pharma in Reverse Takeover Transaction 33
Tiziana Life Sciences Plc, Key Competitors 34
Tiziana Life Sciences Plc, Key Employees 35
Tiziana Life Sciences Plc, Other Locations 36
Tiziana Life Sciences Plc, Subsidiaries 36

List of Figures
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Tiziana Life Sciences Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Tiziana Life Sciences Plc (TILS)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Tennessee Valley Authority：電力：M&Aディール及び事業提携情報
    Summary Tennessee Valley Authority (TVA) is a corporate agency providing electricity for business customers, local power companies and distributors. The agency generates power using diverse sources of energy such as hydro, nuclear, coal, diesel generator and other renewable based power plants. TVA p …
  • Pan American Silver Corp：企業の戦略・SWOT・財務分析
    Pan American Silver Corp - Strategy, SWOT and Corporate Finance Report Summary Pan American Silver Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • SoftTech Yazılım Teknolojileri Arastırma Gelistirme ve Pazarlama Ticaret A.S.：企業の戦略・SWOT・財務情報
    SoftTech Yazılım Teknolojileri Arastırma Gelistirme ve Pazarlama Ticaret A.S. - Strategy, SWOT and Corporate Finance Report Summary SoftTech Yazılım Teknolojileri Arastırma Gelistirme ve Pazarlama Ticaret A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data a …
  • Ferguson Enterprises Inc：企業の戦略的SWOT分析
    Ferguson Enterprises Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Associated Milk Producers Inc.：企業の戦略・SWOT・財務分析
    Associated Milk Producers Inc. - Strategy, SWOT and Corporate Finance Report Summary Associated Milk Producers Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • American Bio Medica Corp (ABMC)：企業の財務・戦略的SWOT分析
    Summary American Bio Medica Corp (ABMC) is a biotechnology company that develops, manufactures and markets immunoassay test kits. The company’s products include Rapid TOX, a point of collection testing product that detects 1-10 drugs of abuse in a urine specimen; Rapid One, a test cassette which is …
  • Allgeier SE (AEIN)：企業の財務・戦略的SWOT分析
    Allgeier SE (AEIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • UnitedHealth Group Inc (UNH)：企業の財務・戦略的SWOT分析
    UnitedHealth Group Inc (UNH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • ASIT Biotech SA (ASIT)：企業の財務・戦略的SWOT分析
    Summary ASIT Biotech SA (ASIT Biotech), formerly BioTech Tools SA is a clinical stage biopharmaceutical company that develops in-vitro and in-vivo biotech tools. The company develops and commercializes immunotherapy medicines for respiratory and food allergies using ASIT plus technology platform. It …
  • Samsung SDS Co Ltd (018260)：企業の財務・戦略的SWOT分析
    Samsung SDS Co Ltd (018260) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Investment Technology Group, Inc.
    Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Blue Apron Inc. (APRN)：企業の財務・戦略的SWOT分析
    Blue Apron Inc. (APRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Asatsu-DK Inc.：企業の戦略的SWOT分析
    Asatsu-DK Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Iovance Biotherapeutics Inc (IOVA)：企業の財務・戦略的SWOT分析
    Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Nature’s Sunshine Products Inc (NATR)：企業の財務・戦略的SWOT分析
    Summary Nature's Sunshine Products Inc (Nature's Sunshine) is a manufacturer and marketer of nutritional and personal care products. The company’s products comprise daily essential pack, probiotics, antioxidants, enzymes, vitamins and minerals, general cleansers, fiber, meal replacement and protein, …
  • Pioneer Natural Resources Co (PXD)-石油・ガス分野：企業M&A・提携分析
    Summary Pioneer Natural Resources Company (Pioneer) is an independent oil and natural gas exploration and production company. Its principally operates in Eagle Ford Shale, Permian Basin, Raton Basin, and West Panhandle. In Permian Basin, the company carries out its exploration and production activit …
  • Murree Brewery Co. Ltd.：企業の戦略・SWOT・財務情報
    Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Faron Pharmaceuticals Oy (FARN)-製薬・医療分野：企業M&A・提携分析
    Summary Faron Pharmaceuticals Oy (Faron Pharma) is a drug company that carries out clinical stage drug discovery and development. The company's product portfolio includes traumakine; clevegen; farbetic, an AOC3 inhibitor and D-ARDS, a diagnostic tool. Its traumakine clinical programme manages the tr …
  • NanoRepro AG (NN6)：製薬・医療：M&Aディール及び事業提携情報
    Summary NanoRepro AG (NanoRepro) is a manufacturer of fast-diagnostics and nutritional food supplements for home and clinical use. The company offers wide range of rapid diagnostic tests products in the areas of family planning, disease detection (preventive healthcare), food intolerances, allergies …
  • New Sports Group Limited：企業のM&A・事業提携・投資動向
    New Sports Group Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's New Sports Group Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆